TriangleNCT01492088 · CITED IN SOURCE DOCUMENTS
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1, PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2024-05-30
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1)
Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1)
Number of Participants With Clinically Significant Vital Signs Values Reported as AEs (Phase 1)
Antibody-drug Conjugate (ADC) Serum Concentrations (Phase 1)
Serum Concentration of Total Antibodies (Conjugated and Unconjugated) (Phase 1)
Monomethyl Auristatin E (MMAE) Plasma Concentrations (Phase 1)
Overall Response Rate (ORR) (Phase 1 and 2)
Number of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing ATA (nATA) (Phase 1 and 2)
Overall Response Rate (ORR) (Phase 1)
Time to Progression (TTP) (Phase 1 and 2)
Time to Response (Phase 1 and 2)
Duration of Response (DOR) (Phase 1 and 2)
Event Free Survival (EFS) (Phase 1 and 2)
Progression Free Survival (PFS) (Phase 1 and 2)
Overall Survival (OS) (Phase 1 and 2)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1 and 2)
Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1 and 2)
Number of Participants With Clinically Significant Vital Signs Reported as AEs (Phase 1 and 2)
Antibody-drug Conjugate (ADC) Serum Concentrations (Phase 1 and 2)
Serum Concentration of Total Antibodies (Conjugated and Unconjugated)
Monomethyl Auristatin E (MMAE) Plasma Concentrations (Phase 1 and 2)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Male or female participants aged 2 to \<18 years (5 to \<18 years for Hodgkin lymphoma \[HL\]) * Diagnosis of systemic anaplastic large-cell lymphoma (sALCL), or HL for which standard, curative, life-prolonging, or palliative treatment does not exist or is no longer effective * Participants with sALCL must have documented anaplastic lymphoma kinase (ALK) status and must be beyond first remission or refractory to front-line chemotherapy * Participants diagnosed with any relapsed or refractory CD30+ hematologic malignancy (e.g., primary mediastinal B-cell lymphoma) may be included in phase 1 of the study * Participants with HL must be in their second of later relapse, have failed systemic chemotherapy either as induction therapy for advanced stage disease or salvage therapy, and were ineligible for, refused, or previously received a stem cell transplant * Performance score ≥ 60 from Lansky Play Performance Scale if ≤16 years * Negative pregnancy test * Fertile Participants must use 2 effective methods of contraception prior to and through 6 months after the last dose of the study drug Exclusion Criteria: * Current diagnosis of primary cutaneous ALCL (those with systemic ALCL are eligible) * Received an allogeneic stem cell transplant \<3 months prior to the first dose of study medication, or presence of polymerase chain reaction (PCR)-detectable cytomegalovirus (CMV) in any post-allogeneic transplant participant * Receiving immunosuppressive therapy * Receiving systemic therapy for chronic graft-versus-host disease (topical therapy is allowed) * Previous treatment with any anti-CD30 antibody * Therapeutic monoclonal antibody use within the longer of 6 weeks or 5 plasma half-lives * Systemic cardiac disease that would, in the opinion of the investigator or medical monitor, interfere with assessment of efficacy or safety of the drug * History of another primary malignancy not in remission for at least 3 years (the following are exempt from the 3-year limit: nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear) * Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML * History of cirrhosis * Active systemic viral, bacterial, or fungal infection requiring antimicrobial, antiviral therapy or antifungal therapy within 2 weeks prior to the first dose of study drug (routine antimicrobial prophylaxis is acceptable) * Concurrent therapy with other anti-neoplastic or experimental agents * Systemic corticosteroid therapy \<7 days prior to first dose of the study medication * Any serious underlying medical condition that, in the opinion of the investigator or medical monitor, would impair their ability to receive or tolerate the planned treatment * Known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation * Received nitrogen mustard agents, melphalan, or BCNU therapy within 6 weeks prior to the first study dose * Prior autologous hematopoietic stem cell infusion \<4 weeks prior to first study dose * Grade 2 or greater unresolved toxicity from prior antineoplastic therapy * Grade 2 or greater peripheral neuropathy * Female participants who are both lactating and breastfeeding, or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before the first dose of study drug * Received local palliative radiation therapy \<14 days prior to the first dose of study medication * Received radiation therapy to more than 25% of the bone marrow-containing spaces \< 84 days prior to first dose of study medication * Received a strong or listed moderate inhibitor of CYP3A4 \<2 weeks prior to first study dose * Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
- healthy Volunteers
- false
- maximum Age
- 18 Years
- minimum Age
- 2 Years
- sex
- ALL
- std Ages
- CHILD
- ADULT
Treatment arms and interventions
- arm Groups
- description
- Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
- intervention Names
- Drug: Brentuximab vedotin
- label
- Brentuximab vedotin: Phase 1
- type
- EXPERIMENTAL
- description
- Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
- intervention Names
- Drug: Brentuximab vedotin
- label
- Brentuximab vedotin: Phase 2
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Brentuximab vedotin: Phase 1
- Brentuximab vedotin: Phase 2
- description
- Brentuximab vedotin IV infusion
- name
- Brentuximab vedotin
- other Names
- SGN-35
- ADCETRIS
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 36
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
- measure
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1)
- time Frame
- From the first dose through 30 days after the last dose of study medication (Up to 15 months)
- description
- Abnormal clinical laboratory values (serum chemistry and hematology) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
- measure
- Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1)
- time Frame
- From the first dose through 30 days after the last dose of study medication (Up to 15 months)
- description
- Vital signs measurements included supine (after 3-5 minutes in this position) and standing (after 3-5 minutes in this position) measurements of diastolic and systolic blood pressure, heart rate, and oral temperature.
- measure
- Number of Participants With Clinically Significant Vital Signs Values Reported as AEs (Phase 1)
- time Frame
- From the first dose through 30 days after the last dose of study medication (Up to 15 months)
- description
- Blood samples were collected and tested for serum concentrations of brentuximab vedotin antibody-drug conjugate.
- measure
- Antibody-drug Conjugate (ADC) Serum Concentrations (Phase 1)
- time Frame
- Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose
- description
- Blood samples were collected and tested for conjugated and unconjugated antibodies.
- measure
- Serum Concentration of Total Antibodies (Conjugated and Unconjugated) (Phase 1)
- time Frame
- Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose
- description
- Blood samples were collected and tested for MMAE plasma concentrations.
- measure
- Monomethyl Auristatin E (MMAE) Plasma Concentrations (Phase 1)
- time Frame
- Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose
- description
- Overall response rate is defined as the percentage of participants with complete remission (CR) or partial remission (PR) as assessed by an independent review facility (IRF) using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
- measure
- Overall Response Rate (ORR) (Phase 1 and 2)
- time Frame
- Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or end of treatment (EOT) (Up to 15 months)
- secondary Outcomes
- description
- Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA and nATA development) using a laboratory test. ATA-positive samples were further characterized as transiently ATA positive (defined as 1 or 2 post-Baseline ATA-positive responses), persistently ATA positive (defined as more than 2 post-Baseline ATA positive responses), and nATA positive or negative.
- measure
- Number of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing ATA (nATA) (Phase 1 and 2)
- time Frame
- Baseline up to EOT (Up to 15 months)
- description
- Overall response rate is defined as the percentage of participants with CR or PR as assessed by an IRF using IWG Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
- measure
- Overall Response Rate (ORR) (Phase 1)
- time Frame
- Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT (Up to 15 months)
- description
- TTP is defined as the time in months from first dose until the first subsequent documentation of objective tumor progression. Progressive disease (PD) is defined as any new lesion or increase by ≥50% of previously involved sites from nadir.
- measure
- Time to Progression (TTP) (Phase 1 and 2)
- time Frame
- Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death (Up to 27 months)
- description
- Time to response is defined as the time in months from the first dose of study treatment until the date of the first assessment of confirmed CR or PR. as assessed by an IRF using IWG revised response criteria for malignant lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
- measure
- Time to Response (Phase 1 and 2)
- time Frame
- Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT (Up to 15 months)
- description
- DOR is defined as the time in months from the date of first documentation of a CR or PR to the date of first documentation of tumor progression or PD per IRF assessment according to IWG criteria or to death due to any cause, whichever comes first. CR is defined as the disappearance of all evidence of disease and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
- measure
- Duration of Response (DOR) (Phase 1 and 2)
- time Frame
- Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death or end of study (Up to 72 months)
- description
- EFS is defined as the time in months from first dose until any cause of treatment failure: disease progression, premature discontinuation of treatment for any reason, or death due to any cause, whichever occurs first. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
- measure
- Event Free Survival (EFS) (Phase 1 and 2)
- time Frame
- Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death (Up to 27 months)
- description
- PFS is defined as time in months from start of study treatment to first documentation of objective tumor progression per IRF assessment or up to death due to any cause, whichever occurs first. PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
- measure
- Progression Free Survival (PFS) (Phase 1 and 2)
- time Frame
- Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death or end of study (Up to 72 months)
- description
- OS is the time in months from start of study treatment to date of death due to any cause.
- measure
- Overall Survival (OS) (Phase 1 and 2)
- time Frame
- Every 6 months after EOT, until the sooner of death, study closure, or 2 years after enrolment of the last participant (Up to 72 months)
- description
- An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
- measure
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1 and 2)
- time Frame
- From the first dose through 30 days after the last dose of study medication (up to 15 months)
- description
- Abnormal clinical laboratory values (serum chemistry and hematology) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
- measure
- Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1 and 2)
- time Frame
- From the first dose through 30 days after the last dose of study medication (Up to 15 months)
- description
- Vital signs measurements included supine (after 3-5 minutes in this position) and standing (after 3-5 minutes in this position) measurements of diastolic and systolic blood pressure, heart rate, and oral temperature.
- measure
- Number of Participants With Clinically Significant Vital Signs Reported as AEs (Phase 1 and 2)
- time Frame
- From the first dose through 30 days after the last dose of study medication (Up to 15 months)
- description
- Blood samples were collected and tested for serum concentrations of brentuximab vedotin antibody-drug conjugate.
- measure
- Antibody-drug Conjugate (ADC) Serum Concentrations (Phase 1 and 2)
- time Frame
- Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose
Full study description
- brief Summary
- The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
- detailed Description
- The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat children who have relapsed or refractory (r/r) anaplastic large-cell lymphoma (sALCL) or Hodgkin lymphoma (HL). This study will look at the maximum tolerated dose and/or recommended phase 2 dose, safety and pharmacokinetics of brentuximab vedotin along with overall response of people who took brentuximab vedotin. The study enrolled 36 patients. In the phase 1 portion of the study, 12 participants were enrolled to receive brentuximab vedotin 1.4-1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Once the maximum tolerated dose and/or recommended phase 2 dose and pharmacokinetics of brentuximab vedotin was reached, participants were enrolled by diagnosis into two phase 2 study arms: relapsed or refractory sALCL or relapsed or refractory HL and received brentuximab vedotin 1.8 mg/kg as 30-minute IV on Day 1 of every 21-day cycle for up to 16 cycles. One participant received a maximum of 20 cycles at the joint discretion of the sponsor and the investigator for continued clinical benefit. This multicenter trial is being conducted worldwide. The overall time to participate in this study is approximately 5 years. Participants made multiple visits to the clinic, and were contacted by telephone every 12 weeks for 12 months after the end of treatment (EOT) for progression free survival and then every 6 months until death, study closure, or 2 years after enrollment of the last participant for overall survival.
Source references
- references
- citation
- Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.
- pmid
- 17242396
- type
- RESULT
- citation
- Suri A, Mould DR, Song G, Kinley J, Venkatakrishnan K. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens. J Clin Pharmacol. 2020 Dec;60(12):1585-1597. doi: 10.1002/jcph.1682. Epub 2020 Jun 28.
- pmid
- 32596842
- type
- DERIVED
- citation
- Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A, August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri A, Gore L. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018 Oct;5(10):e450-e461. doi: 10.1016/S2352-3026(18)30153-4.
- pmid
- 30290902
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-73f91f33b3dc1791dc73
- requested nct id
- NCT01492088
- primary nct id
- NCT01492088
- source kind
- fda_spl_label
- source record id
- a695c1a2-3acc-468b-a829-c8761dc041f6
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- 4856b893b5b6e9b9e23960de1f65a808f45b8d75fed723efad8c4b75e532ba7e
- payload
- application numbers
- BLA125388
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-73f91f33b3dc1791dc73
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01492088
- occurrences
- context exact
- dentified in this study. ADCETRIS Monotherapy The safety and effectiveness of ADCETRIS monotherapy was assessed but have not been established based on a study (NCT01492088) in 36 patients, which included 15 pediatric patients age 8 to less than 17 with relapsed or refractory cHL. No new safety signals were identified in this stud
- end
- 2530
- exact text
- NCT01492088
- start
- 2519
- context exact
- ry Systemic ALCL (sALCL) ADCETRIS monotherapy The safety and effectiveness of ADCETRIS monotherapy was assessed but have not been established based on a study (NCT01492088) in 36 patients, which included 16 pediatric patients age 7 to less than 17 with sALCL. No new safety signals were identified in this study. Newly Diagnosed AL
- end
- 2884
- exact text
- NCT01492088
- start
- 2873
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/87/pediatric_use/0
- source kind
- fda_spl_label
- source record id
- a695c1a2-3acc-468b-a829-c8761dc041f6
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 5fddf8d40b6b981f8ce33b09d0b283f2efc8eb1c1e8cd6a953915476c52641c3
- spl effective time
- 20251111
- spl set id
- 3904f8dd-1aef-3490-e48f-bd55f32ed67f
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-f204afc4c8bf83a4d292
- requested nct id
- NCT01492088
- primary nct id
- NCT01492088
- source kind
- fda_spl_label
- source record id
- a695c1a2-3acc-468b-a829-c8761dc041f6
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- 3154c957a55ede56601c44c78e0ef1bdb2976902c7f4a46ddf0ad403b70d574b
- payload
- application numbers
- BLA125388
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-f204afc4c8bf83a4d292
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01492088
- occurrences
- context exact
- dentified in this study. ADCETRIS Monotherapy The safety and effectiveness of ADCETRIS monotherapy was assessed but have not been established based on a study (NCT01492088) in 36 patients, which included 15 pediatric patients age 8 to less than 17 with relapsed or refractory cHL. No new safety signals were identified in this stud
- end
- 6161
- exact text
- NCT01492088
- start
- 6150
- context exact
- ry Systemic ALCL (sALCL) ADCETRIS monotherapy The safety and effectiveness of ADCETRIS monotherapy was assessed but have not been established based on a study (NCT01492088) in 36 patients, which included 16 pediatric patients age 7 to less than 17 with sALCL. No new safety signals were identified in this study. Newly Diagnosed AL
- end
- 6515
- exact text
- NCT01492088
- start
- 6504
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/87/use_in_specific_populations/0
- source kind
- fda_spl_label
- source record id
- a695c1a2-3acc-468b-a829-c8761dc041f6
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- a46392d9a2093349fc406103138d6e5d6053d98858d6828d6c9435ca4d8004fb
- spl effective time
- 20251111
- spl set id
- 3904f8dd-1aef-3490-e48f-bd55f32ed67f
Preserved source evidence · Not medical advice